Ono Teams Separately With Onyx And Concordia To Continue Its In-Licensing Oncology Expansion
This article was originally published in The Pink Sheet Daily
Executive Summary
Ono will pay Onyx approximately $60 million upfront, up to $287 million in development and sales milestones, and double-digit royalties on net sales for the Japanese rights of all oncology indications for protease inhibitors carfilzomib and ONX 0912.
You may also be interested in...
Merck Products Give Ono Pharma Renewed Life In Japan
TOKYO - Ono Pharma's drug portfolio is "going from maturity to decline," according to a Bank America Merrill Lynch analyst, but there are signs that in-licensed products from Merck, particularly antiemetic Emend (aprepitant), could bring new life to the company
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.